Mucopolysaccharidosis Treatment Market Report Examines Industry Trends, Growth Drivers And Future Outlook

The mucopolysaccharidosis treatment market is poised for significant expansion over the coming years, driven by advancements in medical technology and growing healthcare investments. As research intensifies around gene therapies and rare disease screening improves, this market is set to transform treatment options for patients worldwide. Let's explore the projected market size, leading companies, emerging trends, and key segments shaping the future of mucopolysaccharidosis care.

Forecasted Market Size of the Mucopolysaccharidosis Treatment Market by 2030
The global mucopolysaccharidosis treatment market is projected to reach $3.79 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.0%. This growth is fueled by ongoing progress in gene therapy research, increased funding in healthcare sectors, enhanced rare disease screening initiatives, broader reimbursement policies, and the expansion of precision medicine platforms. Key developments anticipated during the forecast period include improvements in enzyme replacement therapies, wider acceptance of stem cell transplantation, accelerated gene therapy innovations, intensified focus on early diagnosis and newborn screening, and growth in specialized treatment centers.

The mucopolysaccharidosis treatment market size has grown strongly in recent years. It will grow from $2.58 billion in 2025 to $2.78 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to limited awareness of mps disorders, high treatment costs, slow adoption of enzyme therapy, restricted clinical trial availability, reliance on international drug supply.

Download a free sample of the mucopolysaccharidosis treatment market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11942&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Players Driving Innovation in the Mucopolysaccharidosis Treatment Market
Several influential companies dominate the mucopolysaccharidosis treatment landscape, including BioMarin Pharmaceuticals Inc., Sanofi S.A., Takeda Pharmaceutical Co. Ltd., JCR Pharmaceuticals Co. Ltd., Ultragenyx Pharmaceutical Inc., RegenxBio Inc., Sangamo Therapeutics Inc., Audentes Therapeutics Inc., Abeona Therapeutics Inc., Immusoft Corporation, Neurogene Inc., Mallinckrodt Pharmaceuticals, Green Cross Corporation, Denali Therapeutics Inc., Passage Bio Inc., Homology Medicines Inc., AVROBIO Inc., Rocket Pharmaceuticals Inc., Taysha Gene Therapies Inc., Freeline Therapeutics Holdings plc, 4D Molecular Therapeutics Inc., Sio Gene Therapies Inc., SpliceBio S.L., LogicBio Therapeutics Inc., Orchard Therapeutics plc, and Asklepios BioPharmaceutical Inc.

A notable event occurred in January 2024 when Japan-based Kyowa Kirin Co., Ltd. acquired UK-based Orchard Therapeutics for an undisclosed sum. This acquisition merges Kyowa Kirin's extensive biopharmaceutical capabilities with Orchard's innovative gene therapy platform, aimed at providing transformative treatments for patients with severe genetic disorders such as mucopolysaccharidosis.

View the full mucopolysaccharidosis treatment market report:
https://www.thebusinessresearchcompany.com/report/mucopolysaccharidosis-treatment-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends Shaping the Global Mucopolysaccharidosis Treatment Market
Innovations in the MPS II treatment segment are gaining momentum as companies focus on developing AAV gene therapies designed to directly address the genetic causes of the disease and offer lasting neurological benefits. Adeno-associated viral (AAV) gene therapy involves delivering functional genes into central nervous system cells, enabling continuous production of deficient proteins.

For instance, in August 2025, US-based REGENXBIO Inc. announced that the FDA extended its review of RGX-121 after receiving longer-term clinical data from pivotal study participants. The data showed consistent biomarker and neurodevelopmental outcomes, while clean pre-license inspections and no safety concerns reinforced ongoing regulatory support. This progress strengthens RGX-121's potential as the first one-time gene therapy targeting the neurological symptoms of MPS II.

Key Segments Included in the Mucopolysaccharidosis Treatment Market Report
This report divides the mucopolysaccharidosis treatment market into several important categories:

1) Treatment Types: Enzyme Replacement Therapy and Stem Cell Therapy
2) Disease Variants: Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis IV, Mucopolysaccharidosis VI, and other less common variants
3) Administration Routes: Intravenous and Intracerebroventricular delivery
4) End-User Categories: Hospitals, Specialty Clinics, and other healthcare settings

Further detailed subsegments include:
- Enzyme Replacement Therapy options such as Idursulfase (Elaprase), Laronidase (Aldurazyme), Velaglucerase Alfa (Vpriv), and Galsulfase (Naglazyme)
- Stem Cell Therapies encompassing Hematopoietic Stem Cell Transplantation (HSCT), Umbilical Cord Blood Transplantation, and various gene therapy approaches

This comprehensive segmentation provides a clear understanding of the diverse treatment methods and healthcare environments contributing to the market's development.

What's new in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel dashboards
• Market hotspots infographics
• Key technologies and future trends
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.